REFERENCES
- Aronoff G, Brier M, Mayer M L, et al. Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. J Clin Pharmacol 1991; 31: 38–44
- Singh B N, Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J 1974; 87: 367–382
- Hellestrand K J, Burnett P J, Milne J R, et al. Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds. Pacing Clin Electrophysiol 1983; 6: 892–899
- Brazzell R K, Aogaichi K, Heger J J, Jr, et al. Cibenzoline plasma concentration and antiarrhythmic effect. Clin Pharmacol Ther 1984; 35: 307–316
- Brazzell R K, Rees M M, Khoo K C, et al. Age and cibenzoline disposition. Clin Pharmacol Ther 1984; 36: 613–619
- Massarella J W, Khoo K C, Aogaichi K, et al. Effect of renal impairment on the phamacokinetics of cibenzoline. Clin Pharmacol Ther 1988; 43: 317–323
- Khoo K C, Szuna A J, Colburn W A, et al. Single-dose pharmacokinetics and dose proportionality of oral cibenzoline. J Clin Pharmacol 1984; 24: 283–288